Description:
A next-generation triple-action weight loss peptide, RT3 is an investigational triple agonist targeting GIP, GLP-1, and glucagon receptors simultaneously. Phase 2 trials have shown up to 24% weight loss at the highest dose — the highest recorded for any obesity medication. It represents the next generation of metabolic therapies.

Core Benefits:

• Exceptional weight loss
  Potentially the most effective weight loss medication ever studied.
• Triple mechanism
  First-in-class triple agonist targeting GIP, GLP-1, and glucagon receptors for maximum metabolic impact.
• Enhanced energy expenditure
  Glucagon receptor activation increases thermogenesis and energy use — burning more calories even at rest.
• Superior glucose control
  Significant improvements in blood sugar levels, with near-normalization of A1C in many trial participants.